ANCIENT ENZYMES, MODERN MEDICINE: WHAT WAGENINGEN’S CANNABIS DISCOVERY MEANS

Researchers at Wageningen University published a breakthrough in Nature that reframes our understanding of cannabis biochemistry. They identified ancestral enzymes in cannabis that produce CBC (cannabichromene)—a cannabinoid most consumers have never heard of—as potentially the plant’s original cannabinoid.

The implications are significant. Modern cannabis has been bred almost exclusively for THC and CBD production. But the evolutionary history of the plant suggests CBC and other minor cannabinoids were the primary output for millions of years. These ancestral pathways were suppressed by selective breeding, not eliminated.

The team used molecular phylogenetics to reconstruct the evolutionary history of cannabinoid synthase enzymes, demonstrating that the CBC pathway predates both THCA and CBDA synthesis. In practical terms, this means the enzymes that produce CBC are more genetically stable and potentially more efficient.

For the cannabinoid industry, this opens a door: if CBC production can be optimized using these ancestral enzymes—whether in planta or via biosynthesis—it could unlock commercial-scale production of a cannabinoid with documented anti-inflammatory, analgesic, and neuroprotective properties.

This is the kind of research that reminds us why the regulatory debate matters. Without legal clarity, American researchers and companies can’t capitalize on discoveries like this. The science is advancing. The law is retreating.